CLX

Business profile & competitive position

The Clorox Company is a Consumer Defensive name in the Household & Personal Products industry. It manufactures and markets consumer and professional products globally, with fiscal 2026 net sales of $6.7 billion, roughly 9,200 employees, operations in about 25 countries, and sales in roughly 95 markets. Consumer brands include Clorox, Pine-Sol, Glad, Fresh Step, Kingsford, Hidden Valley, Brita, and Burt’s Bees, while professional products are sold under Purell, CloroxPro, and Clorox Healthcare. In April 2026, Clorox completed the acquisition of GOJO Industries, adding the Purell hand-hygiene franchise and deepening its business-to-business health and hygiene footprint.

The company’s reported net margin is 8.7%, which is modest for a household-products portfolio and does not suggest an unusually wide economic moat on its own. The ROE figure of -1,893.5% is extreme and is best read as a balance-sheet artifact, most likely driven by negative or very low shareholders’ equity rather than a straightforward profitability read. Concentration risk is tangible: Walmart accounted for 26% of consolidated fiscal 2026 net sales, and the five largest customers represented about half of consolidated net sales. The Glad bags and wraps venture with Procter & Gamble expired on January 31, 2026, after which Clorox purchased P&G’s 20% interest; Glad retained core intellectual property licenses on a royalty-free basis. Fiscal 2026 also saw diluted EPS fall 26%, partly because ERP transition timing had pulled some sales into fiscal 2025.

Financial posture

Clorox currently carries a $10.5 billion market capitalization and trades at a P/E of 18.0, a valuation that sits in the middle range for large-cap consumer staples. Its beta is 0.57, implying noticeably lower market sensitivity than the average stock, consistent with the defensive nature of the Household & Personal Products classification. The 8.7% net margin underlines that this is a business with meaningful costs to manage, from commodity inputs to advertising and trade spending, rather than a high-margin powerhouse.

Because the ROE is deeply negative, conventional return-on-equity analysis is not useful here; the figure is almost certainly distorted by the equity base. The more relevant profitability context is the sales scale ($6.7 billion in fiscal 2026 net sales) against the 26% EPS decline recorded that year. With the GOJO integration underway and the Glad venture restructured, the balance sheet and cash-flow mix are likely to matter as much as headline earnings for the next few quarters.

Strategic priorities & outlook

According to the company’s most recent 10-K filing, Clorox is organized around its IGNITE strategy, which has four stated choices: fueling long-term profitable growth, innovating consumer experiences, reimagining how the company and its people work, and continuously evolving the product portfolio. A major operational priority is completing and optimizing a new enterprise resource planning (ERP) system and broader digital transformation. Management describes the goal as generating long-term efficiencies across supply chain, digital commerce, innovation, and brand building.

The filing also highlights three additional levers: investing in strong brands and strategic digital capabilities, streamlining the operating model to build a more resilient company, and advancing health and hygiene expansion through the GOJO integration and growth in professional and institutional markets. These priorities suggest the company is trying to offset macro pressure with internal productivity and portfolio shifts rather than relying on volume tailwinds alone.

Macro & geopolitical exposure

Because Clorox sits in Consumer Defensive / Household & Personal Products, its exposures are the classic ones for the sector. Raw-material costs, including resins, chemicals, pulp, and energy, directly affect packaging and product margins. Logistics and labor costs also move through the income statement, and persistent inflation can pressure either gross margins or pricing power if consumers trade down to private-label alternatives.

Customer concentration amplifies retailer negotiating leverage, especially when nearly a quarter of sales move through a single channel. Foreign-exchange risk is present because roughly 95 markets are served, although the U.S. is presumably the largest. Regulatory exposure includes EPA registration for disinfectants and general consumer-product safety rules, while consumer sentiment and employment trends drive discretionary portions of the portfolio, such as Burt’s Bees and Kingsford. Tariffs or trade-policy shifts can add cost volatility to imported materials or finished goods, though the company’s broad geographic footprint provides some natural hedging.

Recent developments

Recent headlines have been cautious. On October 26, 2026, Fool.com published “Macroeconomic Headwinds are Hitting Clorox From All Sides,” the same day it asked, “Should You Forget Clorox Stock Near a 52-Week Low?” Zacks.com also weighed in on October 26, 2026, with “Clorox (CLX) Earnings Expected to Grow: Should You Buy?” A day earlier, on October 25, 2026, 247wallst.com ran “Whirlpool's Dividend Collapse Is a Warning for These 3 High-Yield Stocks,” a piece that frames Clorox within a broader dividend-risk conversation rather than a company-specific event. Collectively, this news cluster points to market debate about growth, payout sustainability, and valuation near what the price action suggests is a depressed level, not a clear fundamental verdict.

Earnings behavior & post-earnings drift

Clorox has beaten earnings estimates in 6 of the last 8 reported quarters, a 75% beat rate, with an average earnings surprise of 9.6%. Across those same eight quarters, the average five-session price move after earnings has been +1.67%, classified as an “up” post-earnings drift. That said, drift and next-day reaction are not the same thing, and the last four reports illustrate how noisy the relationship can be.

On August 3, 2026, Clorox reported EPS of $1.66 against an estimate of $1.64, a 1.2% beat; the stock rose 6.52% the next day and 9.61% over the following five trading days. On April 30, 2026, EPS of $1.64 beat the $1.55 estimate by 5.8%, yet the stock fell 9.67% the next day and was down 4.49% over five sessions. On February 3, 2026, the company missed by 2.8%, reporting $1.39 versus $1.43, but the stock still rose 2.43% the next day and 5.63% over the next five days. On November 3, 2025, EPS of $0.85 beat the $0.818 estimate by 3.9%, producing a 1.17% next-day gain but a 4.08% decline over the following five sessions. The next report is scheduled for November 2, 2026, after the close, with a consensus EPS estimate of $1.07.

For a fuller picture of how institutional analysts are interpreting the GOJO integration, ERP rollout, dividend coverage, and the November 2 earnings setup, review the complete institutional verdict and consensus breakdown.